NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: A Sufficient Reason to Avoid Gadolinium-Based Contrast in All Patients with Renal Impairment?
- 23 January 2008
- journal article
- review article
- Published by Wiley in Seminars in Dialysis
- Vol. 21 (2) , 140-141
- https://doi.org/10.1111/j.1525-139x.2007.00400.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- New Insights into Nephrogenic Systemic FibrosisJournal of the American Society of Nephrology, 2007
- Nephrogenic Systemic FibrosisClinical Journal of the American Society of Nephrology, 2007
- Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be ConcernedAmerican Journal of Roentgenology, 2007
- Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?The British Journal of Radiology, 2007
- Nephrogenic Systemic Fibrosis Among Liver Transplant Recipients: A Single Institution Experience and Topic UpdateAmerican Journal of Transplantation, 2006
- Dialyzability of gadodiamide in hemodialysis patientsRadiation Medicine, 2006
- Prophylaxis Strategies for Contrast-Induced NephropathyJAMA, 2006
- Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failureJournal of the American Academy of Dermatology, 2006
- Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the LiteratureSeminars in Arthritis and Rheumatism, 2006
- Multiorgan Involvement in Nephrogenic Fibrosing Dermopathy: An Autopsy Case and Review of the LiteratureArchives of Pathology & Laboratory Medicine, 2006